GENSCRIPT BIO (01548): Legend Announces Presentations at 2025 ASH Annual Meeting

Stock News

2025/12/07

GENSCRIPT BIO (01548) announced that Legend Biotech ("Legend," an associate company whose American Depositary Shares are listed on Nasdaq Global Select Market) issued a press release on December 6, 2025 (New York Time), disclosing clinical and translational research data from long-term follow-up of the CARTITUDE-1 and CARTITUDE-4 studies for CARVYKTI (ciltacabtagene autoleucel, cilta-cel) in patients with relapsed or refractory multiple myeloma (RRMM). The latest results from the Phase III CARTITUDE-4 study were also presented via an oral presentation at the 2025 American Society of Hematology (ASH) Annual Meeting. Additionally, six poster presentations showcased CARVYKTI's durability of response across different subgroups and real-world evidence. Legend further presented first-in-human trial data for its dual-target allogeneic CAR-T candidate, LUCAR-G39D, in an oral session at the ASH Annual Meeting.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1160174342"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1160174342\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1160174342?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-07 19:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1160174342","market":"us","top_or_hot":-1,"title":"GENSCRIPT BIO (01548): Legend Announces Presentations at 2025 ASH Annual Meeting","media":"Stock News","content":"<p>GENSCRIPT BIO (01548) announced that Legend Biotech (\"Legend,\" an associate company whose American Depositary Shares are listed on Nasdaq Global Select Market) issued a press release on December 6, 2025 (New York Time), disclosing clinical and translational research data from long-term follow-up of the CARTITUDE-1 and CARTITUDE-4 studies for CARVYKTI (ciltacabtagene autoleucel, cilta-cel) in patients with relapsed or refractory multiple myeloma (RRMM). The latest results from the Phase III CARTITUDE-4 study were also presented via an oral presentation at the 2025 American Society of Hematology (ASH) Annual Meeting. Additionally, six poster presentations showcased CARVYKTI's durability of response across different subgroups and real-world evidence. Legend further presented first-in-human trial data for its dual-target allogeneic CAR-T candidate, LUCAR-G39D, in an oral session at the ASH Annual Meeting.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GENSCRIPT BIO (01548): Legend Announces Presentations at 2025 ASH Annual Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGENSCRIPT BIO (01548): Legend Announces Presentations at 2025 ASH Annual Meeting\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2025-12-07 19:08</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>GENSCRIPT BIO (01548) announced that Legend Biotech (\"Legend,\" an associate company whose American Depositary Shares are listed on Nasdaq Global Select Market) issued a press release on December 6, 2025 (New York Time), disclosing clinical and translational research data from long-term follow-up of the CARTITUDE-1 and CARTITUDE-4 studies for CARVYKTI (ciltacabtagene autoleucel, cilta-cel) in patients with relapsed or refractory multiple myeloma (RRMM). The latest results from the Phase III CARTITUDE-4 study were also presented via an oral presentation at the 2025 American Society of Hematology (ASH) Annual Meeting. Additionally, six poster presentations showcased CARVYKTI's durability of response across different subgroups and real-world evidence. Legend further presented first-in-human trial data for its dual-target allogeneic CAR-T candidate, LUCAR-G39D, in an oral session at the ASH Annual Meeting.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HK0000320223.HKD","symbol_name":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","start_time":0,"source_url":"","article_id":"1160174342","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1160174342","pubTimestamp":1765105695,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"GENSCRIPT BIO (01548) announced that Legend Biotech (\"Legend,\" an associate company whose American Depositary Shares are listed on Nasdaq Global Select Market) issued a press release on December 6,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","BK1583":"高瓴概念","ASH":"Ashland","BK1141":"生命科学工具和服务","01548":"金斯瑞生物科技","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","BK4109":"特种化学制品","BK1576":"医药外包概念","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","LU2463526074.USD":"NORDEA 1 - GLOBAL CLIMATE ENGAGEMENT \"BP\" (USD) ACC"},"translate_title":"金斯瑞生物(01548)：联想宣布在2025年ASH年会上发表演讲","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ASH":1,"01548":1},"content_text":"GENSCRIPT BIO (01548) announced that Legend Biotech (\"Legend,\" an associate company whose American Depositary Shares are listed on Nasdaq Global Select Market) issued a press release on December 6, 2025 (New York Time), disclosing clinical and translational research data from long-term follow-up of the CARTITUDE-1 and CARTITUDE-4 studies for CARVYKTI (ciltacabtagene autoleucel, cilta-cel) in patients with relapsed or refractory multiple myeloma (RRMM). The latest results from the Phase III CARTITUDE-4 study were also presented via an oral presentation at the 2025 American Society of Hematology (ASH) Annual Meeting. Additionally, six poster presentations showcased CARVYKTI's durability of response across different subgroups and real-world evidence. Legend further presented first-in-human trial data for its dual-target allogeneic CAR-T candidate, LUCAR-G39D, in an oral session at the ASH Annual Meeting.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}